Nectar Lifesciences (NSE:NECLIFE) Short Interest


NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
43 GF Score
Price ₹11.58
GF Value ₹6.86
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NSE:NECLIFE vs ZTS, UTHR: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nectar Lifesciences Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Short Interest falls into.


NSE:NECLIFE
43GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹11.58 is trading 68.8% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • Short Interest:
  • GF Value™: ₹6.86 vs. price of ₹11.58 (68.8% above fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
43GF Score

Get the complete analysis for NSE:NECLIFE

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹11.58
Price
₹6.86
GF Value